EXPAND Study
STUDY AND PROTOCOL NUMBER
EXPAND CBAF312A2304
STUDY DETAILS
A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
Further information
ClinicalTrials.gov Identifier: NCT01665144
https://clinicaltrials.gov/ct2/show/NCT01665144?term=BAF312&rank=4